RhumbLine Advisers’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $687K | Buy |
120,403
+2,812
| +2% | +$12.8K | ﹤0.01% | 2551 |
|
|
2026
Q1 | $529K | Sell |
117,591
-158,268
| -57% | -$825K | ﹤0.01% | 2578 |
|
|
2025
Q4 | $1.7M | Sell |
275,859
-14,186
| -5% | -$103K | ﹤0.01% | 1961 |
|
|
2025
Q3 | $2.1M | Sell |
290,045
-14,864
| -5% | -$88.3K | ﹤0.01% | 1884 |
|
|
2025
Q2 | $1.62M | Buy |
304,909
+26,435
| +9% | +$156K | ﹤0.01% | 1997 |
|
|
2025
Q1 | $2.47M | Sell |
278,474
-11,028
| -4% | -$132K | ﹤0.01% | 1707 |
|
|
2024
Q4 | $3.97M | Buy |
289,502
+12,144
| +4% | +$224K | ﹤0.01% | 1538 |
|
|
2024
Q3 | $7.6M | Sell |
277,358
-6,077
| -2% | -$165K | 0.01% | 1195 |
|
|
2024
Q2 | $6.93M | Buy |
283,435
+6,761
| +2% | +$148K | 0.01% | 1215 |
|
|
2024
Q1 | $5.9M | Buy |
276,674
+5,452
| +2% | +$117K | 0.01% | 1323 |
|
|
2023
Q4 | $5.19M | Buy |
271,222
+1,915
| +0.7% | +$33.1K | 0.01% | 1388 |
|
|
2023
Q3 | $4.32M | Buy |
269,307
+1,313
| +0.5% | +$25K | 0.01% | 1447 |
|
|
2023
Q2 | $6.21M | Sell |
267,994
-980
| -0.4% | -$21.4K | 0.01% | 1252 |
|
|
2023
Q1 | $6.25M | Buy |
268,974
+11,282
| +4% | +$229K | 0.01% | 1196 |
|
|
2022
Q4 | $3.74M | Buy |
257,692
+11,059
| +4% | +$206K | 0.01% | 1446 |
|
|
2022
Q3 | $4.71M | Buy |
246,633
+9,030
| +4% | +$207K | 0.01% | 1270 |
|
|
2022
Q2 | $4.32M | Buy |
237,603
+10,562
| +5% | +$219K | 0.01% | 1326 |
|
|
2022
Q1 | $5.72M | Sell |
227,041
-786
| -0.3% | -$20.1K | 0.01% | 1227 |
|
|
2021
Q4 | $6.29M | Sell |
227,827
-2,443
| -1% | -$70.8K | 0.01% | 1236 |
|
|
2021
Q3 | $7.43M | Sell |
230,270
-26,332
| -10% | -$874K | 0.01% | 1119 |
|
|
2021
Q2 | $7.85M | Sell |
256,602
-8,099
| -3% | -$234K | 0.01% | 1150 |
|
|
2021
Q1 | $8.06M | Sell |
264,701
-110
| -0% | -$3.12K | 0.01% | 1131 |
|
|
2020
Q4 | $5.24M | Buy |
264,811
+28,901
| +12% | +$467K | 0.01% | 1330 |
|
|
2020
Q3 | $3.08M | Sell |
235,910
-15,076
| -6% | -$191K | ﹤0.01% | 1446 |
|
|
2020
Q2 | $2.85M | Sell |
250,986
-14,787
| -6% | -$210K | ﹤0.01% | 1530 |
|
|
2020
Q1 | $3.8M | Buy |
265,773
+15,842
| +6% | +$335K | 0.01% | 1194 |
|
|
2019
Q4 | $6.81M | Buy |
249,931
+15,208
| +6% | +$418K | 0.01% | 1072 |
|
|
2019
Q3 | $6.72M | Buy |
234,723
+13,719
| +6% | +$400K | 0.01% | 1021 |
|
|
2019
Q2 | $6.14M | Buy |
221,004
+16,115
| +8% | +$455K | 0.01% | 1085 |
|
|
2019
Q1 | $6.8M | Sell |
204,889
-2,172
| -1% | -$66.1K | 0.01% | 993 |
|
|
2018
Q4 | $6.02M | Buy |
207,061
+45,070
| +28% | +$1.62M | 0.01% | 992 |
|
|
2018
Q3 | $7.45M | Sell |
161,991
-2,378
| -1% | -$106K | 0.01% | 849 |
|
|
2018
Q2 | $6.14M | Sell |
164,369
-835
| -0.5% | -$28.2K | 0.01% | 965 |
|
|
2018
Q1 | $4.88M | Buy |
165,204
+2,985
| +2% | +$101K | 0.01% | 1053 |
|
|
2017
Q4 | $5.57M | Buy |
162,219
+24,839
| +18% | +$838K | 0.01% | 1003 |
|
|
2017
Q3 | $4.97M | Buy |
137,380
+3,575
| +3% | +$102K | 0.01% | 1041 |
|
|
2017
Q2 | $3.46M | Buy |
133,805
+2,047
| +2% | +$43.5K | 0.01% | 1225 |
|
|
2017
Q1 | $2.53M | Buy |
131,758
+55,301
| +72% | +$980K | 0.01% | 1416 |
|
|
2016
Q4 | $1.27M | Buy |
76,457
+4,283
| +6% | +$77.5K | ﹤0.01% | 1715 |
|
|
2016
Q3 | $1.49M | Buy |
72,174
+1,584
| +2% | +$40.2K | ﹤0.01% | 1596 |
|
|
2016
Q2 | $2.16M | Buy |
70,590
+270
| +0.4% | +$9.38K | 0.01% | 1290 |
|
|
2016
Q1 | $2.63M | Buy |
70,320
+1,010
| +1% | +$38.1K | 0.01% | 1196 |
|
|
2015
Q4 | $2.99M | Buy |
69,310
+150
| +0.2% | +$6.34K | 0.01% | 1119 |
|
|
2015
Q3 | $2.59M | Buy |
69,160
+1,304
| +2% | +$46.3K | 0.01% | 1177 |
|
|
2015
Q2 | $2.31M | Sell |
67,856
-1,387
| -2% | -$47.2K | 0.01% | 1302 |
|
|
2015
Q1 | $2.45M | Buy |
69,243
+1,650
| +2% | +$59.1K | 0.01% | 1260 |
|
|
2014
Q4 | $2.3M | Sell |
67,593
-1,355
| -2% | -$48.1K | 0.01% | 1255 |
|
|
2014
Q3 | $2.66M | Buy |
68,948
+287
| +0.4% | +$10.7K | 0.01% | 1135 |
|
|
2014
Q2 | $2.67M | Sell |
68,661
-2,820
| -4% | -$105K | 0.01% | 1188 |
|
|
2014
Q1 | $2.44M | Sell |
71,481
-4,284
| -6% | -$133K | 0.01% | 1220 |
|
|
2013
Q4 | $1.59M | Sell |
75,765
-7,087
| -9% | -$179K | ﹤0.01% | 1511 |
|
|
2013
Q3 | $1.95M | Sell |
82,852
-2,044
| -2% | -$58.1K | 0.01% | 1368 |
|
|
2013
Q2 | $2.28M | Buy |
+84,896
| New | +$2.46M | 0.01% | 1216 |
|
Other funds holding MYGN
VPC
RhumbLine Advisers's MYGN Position: Q2 2026 in Review
RhumbLine Advisers increased its Myriad Genetics (MYGN) stake by 2.4% in Q2 2026, buying an estimated $12.8K and bringing the position to 120,403 shares worth $687K. The position accounts for ﹤0.01% of the portfolio, ranked #2551.
RhumbLine Advisers first reported a position in MYGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $8.06M in Q1 2021. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.
- RhumbLine Advisers held 120,403 shares of Myriad Genetics worth $687K as of Q2 2026.
- RhumbLine Advisers bought 2,812 Myriad Genetics shares in Q2 2026, an estimated $12.8K.
- Myriad Genetics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2551 holding.
- RhumbLine Advisers first reported a position in Myriad Genetics in Q2 2013 and has held it in 53 quarters since.
- RhumbLine Advisers's Myriad Genetics position peaked at $8.06M in Q1 2021.
- 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.